← FDA DRUG APPROVALS

FDA NDA · NDA022056

PRILOSEC

omeprazole magnesium

Sponsor: AZURITY

APPLICATION
NDA022056
TYPE
NDA
ORIGINAL APPROVAL
2008-03-20
LATEST ACTION
2023-07-18
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

PRILOSEC · ReferencePrescription
OMEPRAZOLE MAGNESIUM EQ 2.5MG BASE/PACKET · FOR SUSPENSION, DELAYED RELEASE · ORAL
PRILOSEC · ReferencePrescription
OMEPRAZOLE MAGNESIUM EQ 10MG BASE/PACKET · FOR SUSPENSION, DELAYED RELEASE · ORAL

Approval history

2023-07-18Labeling · Supplement 26 · standardLetterAP
2022-03-04Labeling · Supplement 25 · standardLetterAP
2020-11-27Labeling · Supplement 23 · standardLetterAP
2018-08-21Labeling · Supplement 21 · standardLabelAP
2018-06-07Labeling · Supplement 22 · standardLabelAP
2016-12-19Labeling · Supplement 19 · standardLetterAP
2016-10-24Labeling · Supplement 20 · standardLetterAP
2016-02-03Efficacy · Supplement 18 · standardLabelAP
2014-12-19Labeling · Supplement 17 · 901 requiredLabelAP
2014-03-27Labeling · Supplement 14 · standardLabelAP
2014-02-25Labeling · Supplement 15 · 901 requiredLabelAP
2013-05-15Labeling · Supplement 13 · standardLetterAP
2012-10-09Labeling · Supplement 11 · standardLabelAP
2012-09-28Labeling · Supplement 12 · standardLetterAP
2012-01-20Labeling · Supplement 10 · unknownLabelAP
2011-06-30Labeling · Supplement 7 · unknownLabelAP
2011-05-20Labeling · Supplement 9 · 901 requiredLabelAP
2011-01-20Labeling · Supplement 8 · unknownLabelAP
2010-09-03Labeling · Supplement 5 · unknownLetterAP
2010-03-03Labeling · Supplement 3 · unknownLabelAP
2008-12-01Labeling · Supplement 1 · standardLetterAP
2008-03-20Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →